Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

NCT01998035 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

58

Enrollment

OTHER

Sponsor class

Stopped PI left institution

Conditions

Lymphoid Malignancies
Lymphoma
Hodgkin Lymphoma
Non-hodgkin Lymphoma

Interventions

DRUG: RomiDEPsin 10 MG/M2
DRUG: Oral 5-Azacitidine 100 MG
DRUG: Romidepsin 14 MG/M2
DRUG: Oral 5-Azacitidine 200 MG
DRUG: Oral 5-Azacitidine 300 MG

Sponsor

Columbia University

Collaborators

[object Object]